Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Isis is a biopharmaceutical company focused on antisense technology, operating through three segments: Drug Discovery and Development, Ibis Biosciences (infectious disease diagnostics), and Regulus Therapeutics (microRNA therapeutics joint venture). The company relies heavily on strategic alliances and licensing agreements to fund operations and commercialize products.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2007 |
|---|---|---|---|
| Total Revenue | $32,215 | $86,529 | $44,893 |
| Net Income (Loss) | $3,188 | $(3,305) | $(4,037) |
| Net Income (Loss) Applicable to Common Stock | $3,188 | $(3,305) | $(129,348) |
| Operating Expenses | $36,539 | $102,817 | $75,398 |
| Research & Development Expenses | $31,968 | $89,611 | $64,629 |
| Cash and Cash Equivalents | $264,682 | $264,682 | $102,398 |
| Short-term Investments | $247,341 | $247,341 | $55,105 |
| Total Debt (Long-term + Current) | $167,978 | $167,978 | $170,100 |
| Working Capital | $411,860 | $411,860 | $145,112 |
Note: Debt includes $162.5 million in 2 5/8% convertible subordinated notes and $5.478 million in long-term obligations. Working capital is calculated as Total Current Assets ($529,543) minus Total Current Liabilities ($117,683).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the nine months ended September 30, 2008, increased to $86.5 million from $44.9 million in the prior year period. This 93% increase was driven primarily by new collaborations, specifically the Genzyme alliance (licensing fee and equity premium amortization) and the Regulus/GSK alliance.
- Profitability: The company reported a net income of $3.2 million for the quarter ended September 30, 2008, compared to a net income of $20.0 million in the same quarter of 2007. However, on a year-to-date basis, the net loss narrowed significantly to $3.3 million in 2008 compared to a net loss of $4.0 million in 2007. The 2007 comparative period included a $125.3 million non-cash charge related to the acquisition of Symphony GenIsis, which distorted the prior year's net loss applicable to common stock.
- Liquidity Expansion: Cash, cash equivalents, and short-term investments surged to $512.0 million as of September 30, 2008, up from $193.7 million at year-end 2007. This increase was fueled by $325 million from Genzyme, $40.5 million from Abbott, and $20 million from GSK.
- Expense Increases: Operating expenses rose to $102.8 million for the nine months of 2008 from $75.4 million in 2007. This was due to expanded clinical development programs, increased manufacturing costs, and higher stock-based compensation ($11.8 million vs. $7.2 million).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Cash Position: Management expects to end 2008 with a cash balance greater than $450 million, sufficient to fund operations for at least five years.
- Key Programs:
- Mipomersen: Phase 3 studies initiated for heterozygous and homozygous Familial Hypercholesterolemia. FDA guidance indicates an accelerated approval pathway is possible in 2010.
- Ibis Biosciences: Received $20 million additional investment from Abbott in June 2008. Focus remains on commercializing the T5000 Biosensor System.
- Regulus: Strategic alliance with GSK to develop microRNA therapeutics for inflammatory diseases.
- Tax Liability: Due to significant upfront funding in 2008, the company anticipates significant taxable income in 2009 and expects to make estimated tax payments in December 2009.
Risks and Contingencies
- Legal Proceedings:
- Bruker Daltonics: Isis initiated formal dispute resolution regarding unsatisfactory performance by Bruker (manufacturer of Ibis T5000). Litigation is pending in Massachusetts Superior Court.
- Sequenom, Inc.: Filed a patent infringement complaint against Ibis in the U.S. District Court in Delaware in October 2008.
- Accounting Changes: Adoption of FSP No. APB 14-1 in 2009 is expected to significantly increase recorded interest expense due to non-cash amortization of debt discounts.
- Partner Dependence: Revenue is highly concentrated; Partner A (Genzyme) accounted for 36% of revenue in the first nine months of 2008. Termination of key partnerships could materially harm the business.
- Regulatory Risk: Failure to obtain FDA approval for key candidates like mipomersen or the Ibis T5000 system would prevent commercialization.
Investor Verification Checklist
- Deferred Revenue Recognition: Verify the amortization schedule for the $275 million in deferred revenue (Genzyme licensing fee and equity premium) to understand future revenue visibility.
- Legal Dispute Status: Monitor the outcome of the litigation against Bruker Daltonics, as it impacts the manufacturing and commercialization of the Ibis T5000 system.
- Patent Litigation: Assess the potential impact of the Sequenom patent infringement claim on Ibis operations.
- 2009 Tax Impact: Confirm the magnitude of the anticipated 2009 tax liability and its effect on cash flow, given the suspension of California NOL carryforwards.
- Convertible Debt: Review the terms of the $162.5 million convertible notes and the potential dilution upon conversion or the impact of the new accounting standard on interest expense.